AMPK Activation by Metformin Promotes Survival of Dormant ER⁺ Breast Cancer Cells.

ABSTRACT:

Purpose

Despite adjuvant endocrine therapy for patients with estrogen receptor alpha (ER)-positive breast cancer, dormant residual disease can persist for years and eventually cause tumor recurrence. We sought to deduce mechanisms underlying the persistence of dormant cancer cells to identify therapeutic strategies.

Experimental design

Mimicking the aromatase inhibitor-induced depletion of estrogen levels used to treat patients, we developed preclinical models of dormancy in ER⁺ breast cancer induced by estrogen withdrawal in mice. We analyzed tumor xenografts and cultured cancer cells for molecular and cellular responses to estrogen withdrawal and drug treatments. Publicly available clinical breast tumor gene expression datasets were analyzed for responses to neo

SUBMITTER: Hampsch RA 

PROVIDER: S-EPMC7367755 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature